X0206 3 2017-09-27 0 0001654151 Deciphera Pharmaceuticals, Inc. DCPH 0001713712 Flynn Daniel Lee C/O DECIPHERA PHARMACEUTICALS, INC. 500 TOTTEN POND ROAD WALTHAM MA 02451 0 1 0 0 Chief Scientific Officer Stock Option (Right to Buy) 1.89 2025-12-17 Common Stock 625607 D Stock Option (Right to Buy) 1.89 2025-12-17 Common Stock 139029 D Stock Option (Right to Buy) 3.95 2026-09-26 Common Stock 39550 D Stock Option (Right to Buy) 6.13 2027-06-03 Common Stock 151617 D Series A Preferred Stock Common Stock 124695 I By Biochenomix, LLC Series B-1 Preferred Stock Common Stock 8441 I By Biochenomix, LLC Series B-2 Preferred Stock Common Stock 7865 I By Biochenomix, LLC Series C Preferred Stock Common Stock 6048 I By Biochenomix, LLC This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option was 100% exercisable on the date of grant, December 18, 2015. These options are currently options to purchase shares of common stock of Deciphera Pharmaceuticals, LLC, a wholly-owned subsidiary of the Issuer, and will be exchanged for options of the Issuer on a 1 to 5.65 basis immediately prior to the closing of the initial public offering of the Issuer (the "Exchange") pursuant to that certain Reorganization Agreement and Plan of Merger by and among the Issuer, Deciphera Pharmaceuticals, LLC and the other parties named therein, dated September 26, 2017 (the "Merger Agreement"). The amount in this Column 3 reflects the options that will be outstanding following the Exchange. This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of September 30, 2015, subject to continued service through such dates. This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of July 1, 2016, subject to continued service through such dates. This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of May 26, 2017, subject to continued service through such dates. Represents preferred stock of Deciphera Pharmaceuticals, LLC. Upon the closing of the Issuer's initial public offering, each share of preferred stock will automatically be converted into 5.65 shares of common stock of the Issuer. The amount in Column 3 reflects the shares that will be outstanding following the Exchange. Power of Attorney - Exhibit 24 attached /s/ Jeffrey M. Held, Attorney-in-Fact 2018-09-20